JB Chemicals & Pharmaceuticals Limited
JBCHEPHARM · Pharma · NSE
₹2,202
Current Market Price
Fair Value (DCF)
₹1,132
Discount to FV
-48.6%
Updated just now
YieldIQ Score
48/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
57%
ROE
17.1%
Debt/Equity
0.00
WACC
11.0%
Market Cap
₹35,347 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
27.4%
Return on capital employed
EV / EBITDA
29.0×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
84.0×
EBIT covers interest
Current Ratio
3.04×
Short-term liquidity
Asset Turnover
0.92×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.4%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,201.5
Bear case
Discount -216.7%
Base case
Discount -94.5%
Bull case
Discount -44.8%
Ratio Trends
JBCHEPHARM · last 9 annual periods
ROE
17.1%
ROCE
27.4%
Operating Margin
—
Debt / Equity
0.00×
PE
46.7×
EV / EBITDA
29.0×
Historical Financials
JBCHEPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹2424 Cr | ₹3117 Cr | ₹3448 Cr | ₹3862 Cr | ₹4076 Cr | +13.9% |
| EBITDA | ₹583 Cr | ₹705 Cr | ₹933 Cr | ₹1069 Cr | ₹1140 Cr | +18.3% |
| EBIT | ₹510 Cr | ₹591 Cr | ₹796 Cr | — | — | +11.8% |
| PAT | ₹385 Cr | ₹410 Cr | ₹553 Cr | ₹660 Cr | ₹709 Cr | +16.5% |
| EPS (diluted) | ₹49.82 | ₹52.34 | ₹34.85 | — | — | -8.5% |
| CFO | ₹170 Cr | ₹626 Cr | ₹801 Cr | ₹902 Cr | ₹704 Cr | +42.6% |
| CapEx | ₹-707 Cr | ₹-765 Cr | ₹-261 Cr | ₹-120 Cr | ₹-83.2 Cr | — |
| FCF | ₹-537 Cr | ₹-139 Cr | ₹539 Cr | ₹782 Cr | ₹621 Cr | — |
| Total Assets | ₹2607 Cr | ₹3554 Cr | ₹3994 Cr | ₹4274 Cr | ₹4969 Cr | +17.5% |
| Total Debt | ₹54.6 Cr | ₹572 Cr | ₹378 Cr | ₹27.9 Cr | ₹3.6 Cr | -49.4% |
| Shareholders' Equity | ₹2134 Cr | ₹2480 Cr | ₹2923 Cr | ₹3433 Cr | ₹4159 Cr | +18.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
JBCHEPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 EMCURE EMCURE | — | — | Pending | 18.7% | — |
 GLAND GLAND | — | — | Pending | 9.9% | 27.2× |
 AJANTPHARM AJANTPHARM | — | — | Pending | 23.3% | 33.2× |
 IPCALAB IPCALAB | — | — | Pending | 14.2% | 35.6× |
 WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
17 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹61.58/sh
Last payout
2026-02-11
₹12.70
Peak payout
₹12.70
Trailing yield
0.89%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS) trades at 2201.50 vs a model fair value of 1132.06, a gap of -48.6%. Piotroski F-s...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of JBCHEPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for JBCHEPHARM →
Compare
Head-to-head with peers
Compare JBCHEPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse JBCHEPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.